Wells Fargo analyst Benjamin Burnett initiated coverage of Rapport Therapeutics (RAPP) with an Overweight rating and $43 price target The firm thinks the company’s Phase 2a data suggests “best-in-category efficacy” potential in focal onset seizures. Rapport’s long episodes data bring confidence that the placebo response “isn’t overwhelming,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
- Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
- Buy Rating on RAP-219 Underscored by Differentiated Clinical Profile, Conservative Phase 3 Design, and Favorable Risk–Reward
- Rapport Therapeutics Establishes $110 Million At-The-Market Offering
- Rapport Therapeutics advances RAP-219 into Phase 3 epilepsy